

CURRICULUM VITAE

I. PERSONAL INFORMATION

AGNIESZKA DOROTA CZECHOWICZ

Address: Rm. 2351, Biomedical Innovations Building
240 Pasteur Dr., Stanford, CA. 94304
E-Mail: aneeshka@stanford.edu
Office Phone: 650-497-2218
Cell Phone: 650-387-1102

II. ACADEMIC HISTORY

A. Education and Training

09/2001-03/2004	B.S. , Biological Sciences with Honors, Chemistry minor. Stanford University, Stanford, CA. Honors Thesis: Development of a robust human adaptive immune system in CD34+ enriched peripheral blood transplanted mice through use of anti-murine-c-kit monoclonal ACK2. Degree granted 6/2005.
06/2006-06/2010	Ph.D. , Developmental Biology, Stanford University, Stanford, CA. Advisor: Prof. Irving L. Weissman, M.D.. Thesis: <i>Gaining Access to the HSC Niche - Novel Non-Myeloablative Conditioning Approaches</i> .
06/2006-01/2012	M.D. , Scholarly Concentration Molecular Basis of Medicine, Stanford University School of Medicine, Stanford, CA.
07/2009-08/2009	Summer Institute of Entrepreneurship, Stanford University, Graduate School of Business, Stanford, CA. Intensive Mini-MBA program focused on new venture formation.
01/2012-12/2014	Pediatric Residency, Categorical and Integrated Research Tracks, Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Boston, MA. Continuity Clinics in Pediatrics and Pediatric Genetics.
01/2012-02/2017	Post-Doctoral Research Fellow, Stem Cell Biology, Boston Children's Hospital, Boston, MA Advisor: Prof. Derrick Rossi.
01/2015-02/2017	Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship Year I-II, Dana Farber Cancer Institute/ Boston Children's Hospital, Boston, MA. Sub-focus in Stem Cell Transplant.
02/2017-12/2017	Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship Year III, Stanford University/Stanford Children's Health, Stanford, CA. Sub-focus in Bone Marrow Failure.

B. Current Licensure and Certification

2014	Medical Licensure, Commonwealth of Massachusetts No. 261532, expired 8/2017.
2016	Medical Licensure, Medical Board of California No. A146625, expiration 8/2022.
2016	DEA Licensure, registration no FC6372471, expiration 8/2022.
	General Pediatrics Board Certified, Pediatric Hematology/Oncology Board Eligible.

III. ACADEMIC AND PROFESSIONAL APPOINTMENTS

2018-present	Assistant Professor , Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA. Direct a 16-member research laboratory composed of 4 Postdoctoral fellows, 2 Pediatrics M.D. Residents, 1 M.D./Ph.D. student, 2 M.S. students, 2 undergraduate students, 3 Research Scientists and 2 Research Technicians.
2018-present	Member , Stanford University Institute for Stem Cell Biology and Regenerative Medicine
2018-present	Co-lead , Blood Stem Cell Engineering and Transplantation Platform, Stanford Center for Definitive and Curative Medicine.
2018-present	Member , Stanford Center for Definitive and Curative Medicine
2018-present	Member , Stanford University Maternal and Child Health Research Institute
2018-present	Member , Stanford University Diabetes Research Center
2018-present	Member , Stanford University Immunology Program

2018-present **Member**, Stanford University Bio-X
 2018-present **Faculty Mentor**, T32 Training Grant in Medical Scientist Training Program
 2018-present **Faculty Mentor**, T32 Training Grant in Pediatric Nonmalignant Hematology and Stem Cell Biology

IV. HONORS AND AWARDS

2001 Summer Student Award, American Society of Hematology (ASH)
 2005 Achaeur Award for Outstanding Honors Presentation, Stanford University
 2005 Firestone Medal for Excellence in Undergraduate Research, Stanford University
 2005 Honors in Biological Sciences, Stanford University
 2006-2009 Medical Scientist Fellowship, Stanford University Medical Scholars Program
 2007 Young Scientist Travel Grant, International Congress of Immunology
 2007 Trainee Research Award, American Society of Hematology (ASH)
 2007 Late-Breaking Abstract Recipient, American Society of Hematology (ASH)
 2007 Invitee Transplantation Press Conference, American Society of Hematology (ASH)
 2008-2009 Research Training Fellowship, Howard Hughes Medical Institute (HHMI)
 2008-2010 Soros Fellowship, Paul & Daisy Soros Foundation
 2010 Presenter Travel Award, American Society of Hematology (ASH)
 2011 ISSCR Scholarship, California Institute of Regenerative Medicine
 2014 Fred Lovejoy Award, Boston Children's Hospital
 2014 Delegate, International Summit of Achievement, Academy of Achievement
 2015 Potter Fellowship, Boston Children's Hospital / Dana Farber Cancer Institute
 2016 Abstract Achievement Award, American Society of Hematology (ASH)
 2018 Lorry I. Lokey Faculty Scholar, Stanford University School of Medicine
 2019 Baxter Faculty Scholar, Donald E. and Delia B. Baxter Foundation
 2020 New Investigator Award, American Society of Transplantation and Cell Therapy (ASTCT)
 2020 Young Investigator Award, National Comprehensive Cancer Network (NCCN)
 2020 Best Pre-clinical Publication Award, World ADC
 2021 Bronze Prize, Custom Animal Model Awards (CAMA), Taconic-Cyagen
 2021 Outstanding Poster Presentation Award, American Society of Gene and Cell Therapy (ASGCT)

V. SCHOLARLY PUBLICATIONS

A. Original Articles: Peer-Reviewed (17 Total)

1. **Czechowicz A**, Kraft D, Weissman IL, Bhattacharya D. "Efficient Transplantation via Antibody-based Clearance of Hematopoietic Stem Cell Niches." Science. 318(5854):1296-9. 2007.
2. Rossi DJ, Seita J, **Czechowicz A**, Bhattacharya D, Bryder D, Weissman IL. "Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging." Cell Cycle. 6(19):2371-6. 2007.
3. Bhattacharya D, **Czechowicz A**, Ooi L, Rossi D, Bryder D, Weissman IL. "Niche Recycling Through Division-Independent Egress of Hematopoietic Stem Cells." Journal of Experimental Medicine. Nov 23;206(12):2837-50. 2009. [Co-first author]
4. Ahn GO, Tseng D, Liao CH, Dorie MJ, **Czechowicz A**, Brown JM. "Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment." Proc Natl Acad Sci. May 4;107(18):8363-8. 2010.
5. Edris B, Willingham S, Weiskopf K, Volkmer A, Volkmer J, Muhlenberg T, Montgomery K, Contreras-Trujillo H, **Czechowicz A**, Shizuru S, Fletcher J, West R, Weissman I, Van de Rijn M. "Anti-KIT Monoclonal Antibody SR1 Inhibits Growth In Vitro and in Xenotransplantation Models." Proc Natl Acad Sci. Feb 26;110(9):3501-6. 2013.
6. Derderian C, Togarrati P, King C, Moradi P, Reynaud D, Weissman I, **Czechowicz A**, and MacKenzie T. "In Utero Depletion Of Fetal Host Hematopoietic Stem Cells Improves Engraftment Following Neonatal Transplantation In Mice." Blood. 2014 Aug 7;124(6):973-80.

7. Dvorak CC, Horn BN, Puck JM, Adams S, Veys P, **Czechowicz A**, and Cowan MJ. “A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.” Pediatr Transplant. 2014 Sep;18(6):609-16.
8. Dvorak CC, Horn BN, Puck JM, **Czechowicz A**, Shizuru JA, Ko RM, and Cowan MJ. “A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.” Pediatr. Transplant. 2014 Sep;18(6):602-8.
9. Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes D, Tate T, **Czechowicz A**, Kfoury Y, Ruchika F, Rossi D, Verdine G, Mansour M, Scadden D. “Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic cell-specific internalizing immunotoxin.” Nature Biotechnology. 2016 Jul;34(7):738-45. *[Designed and conducted several critical experiments, as well as contributed to data analysis and interpretation. Participated in critical revision of manuscript for important intellectual content.]*
10. Lu R, **Czechowicz A**, Seita J, Juang D, Weissman IL. “Clonal Stability of Hematopoietic Stem Cell Differentiation.” Proc. Natl. Acad. Sci. 2019 Jan 22;116(4):1447-1456. *[Guided scientific direction of section of project. Aided with execution of majority of experiments. Participated in interpretation of data and revision of manuscript for important intellectual content.]*
11. **Czechowicz A**, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang W, Mansour M, Tate T, Chan YY, Walck E, Wernig G, Shizuru J, Winau F, Scadden D, Rossi D. “Selective Hematopoietic Stem Cell (HSC) Ablation using CD117 Antibody-Drug-Conjugates Enables Safe and Effective HSC Transplantation with Preservation of Immunity.” Nature Communications. 2019 Feb 6;10(1):617.
12. Li Z, **Czechowicz A**, Scheck A, Rossi D, and Murphy P. “Robust Hematopoietic Chimerism and Donor-specific Tolerance after Non-genotoxic CD117 Antibody-Drug-Conjugate Conditioning in Fully MHC-mismatched Allotransplantation.” Nature Communications. 2019 Feb 6;10(1):616. *[Co-first author. Spear-headed initial conception of project. Provided intellectual and technical assistance with design of all experiments and interpretation of data. Participated in all aspects of preparation of manuscript and was corresponding author through publication process.]*
13. Pang WW, **Czechowicz A**, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA. “Anti-human CD117 antibody mediates depletion of normal and myelodysplastic syndrome hematopoietic stem cells.” Blood. 2019 May 9;133(19):2069-2078. *[Co-first author. Spear-headed initial conception of first half of the project. Generated data, analyzed results, and determined interpretation of data. Participated in critical revision of manuscript for important intellectual content.]*
14. Kwon H, Logan AC, Chhabra A, Pang WW, **Czechowicz A**, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Thway TM, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA. “Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primate and humanized NSG mice.” Blood. 2019 May 9;133(19):2104-2108. *[Spear-headed initial conception of section of the project. Provided technical assistance with portion of experiments and interpretation of data. Participated in critical revision of manuscript for important intellectual content.]*
15. Gao, C, Schroeder J, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, **Czechowicz A**, Shi Q. “Non-genotoxic antibody-drug-conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.” Blood Advances. 2019 Sep 24; 3(18):2700-2711. *[Spear-headed initial conception of project. Provided continued intellectual and technical assistance with design of all experiments and interpretation of data. Participated in critical revision of manuscript for important intellectual content.]*
16. Kraft D, Walck E, Carrasco A, Crocker M, Song L, Long M, Najar S, Nadeem E, Imanbyev G, Mosse M, **Czechowicz A**, McCullough M. “The MarrowMiner: A Novel, Safe, Effective, and Minimally Invasive Device for the Harvest of Bone Marrow Cells.” Biology of Blood and Marrow

Transplantation. 2020 Feb; 26(2):219-229. [Provided intellectual and technical assistance with interpretation of data. Participated in writing manuscript and played an active role throughout publication process.]

17. Ho P, Zhang Z, Hayes M, Curd A, Dib C, Mayburn M, Tam F, Srivastava T, Hriniak B, Leonard S, Wang L, Tarighat S, Sim D, Fiandaca M, Coull J, Ebens A, Fordyce M, **Czechowicz A**. "Peptide Nucleic Acid-dependent artifact can lead to false-positive triplex gene editing signals." PNAS. 2021 Nov 9; 118(45).

B. Non-peer reviewed journal articles, reviews, editorials, etc. (6 Total)

1. **Czechowicz A**, Kraft D, Weissman IL. "Development of a Robust Human Adaptive Immune System in CD34+ Enriched Peripheral Blood Transplanted Mice Through Use of Anti-Murine-C-Kit Monoclonal Antibody, ACK2." The Stanford Biologist. 5: 79-86. 2005.
2. Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants (incl. **Czechowicz A**). "Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management." J Allergy Clin Immunol. Dec;124(6):1152-60. 2009. [Provided intellectual content. Participated in editing manuscript]
3. **Czechowicz A**, Weissman IL. "Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement. Immunol Allergy Clin North Am. Review. May;30(2):159-71. 2010.
4. **Czechowicz A**, Weissman IL. "Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement. Hematol Oncol Clin North Am. Review. Feb;25(1):75-87. 2011.
5. Cannon P, Asokan A, **Czechowicz A**, Hammond P, Kohn D, Lieber A, Malik P, Marks P, Porteus M, Verhoeven E, Weissman D, Weissman I, Kiem H. "Safe and Effective *In Vivo* Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development." Hum Gene Ther. 2021 Jan;32(1-2):31-42. [Provided intellectual content. Participated in editing manuscript]
6. Van Hentenryck M, Li Z, Murphy P, **Czechowicz A**. "Antibody-Based Immunosuppression and Conditioning in Transplantation. OBM Transplantation. Review. In submission. November 2021.

VI. GRANTS AND FUNDED PROJECTS

A. Current Funding

09/2018 – 08/2022 -- Stanford Lorry Lokey Faculty Scholar

Project Title: *Faculty scholar award*. Role: PI.

09/2019 – 08/2022 -- Ludwig Center for Cancer Stem Cell Research and Medicine

Project Title: *Research support award*. Role: PI.

08/2019 – 07/2023 -- National Institutes of Health – UG3

Project Title: *Delivery technologies for in vivo genome editing*, PD/PI: Elliot Chaikof - Beth Israel Deaconess Medical Center. Role: Co-Investigator.

03/2020 – 02/2025 -- National Institutes of Health

Project Title: *AAV capsid engineering for enhancing gene transfer*. PI: Mark Kay. Role: Co-Investigator.

06/2020 – 05/2024 -- Gabrielle's Angel Foundation

Project Title: *Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia (AML)*. Role: PI.

06/2020 – 05/2023 -- Rocket Pharmaceuticals, Ltd. Sponsored Research Agreement

Project Title: *Master Collaboration Agreement: Phase I/II FANCA exploratory studies*. Role: PI.

07/2020 – 06/2022 -- American Society of Transplantation and Cellular Therapy (ASTCT)

Project Title: Development of combination HSC base-editing and non-genotoxic antibody conditioning.
Role: PI.

07/2020 – 06/2022 -- National Blood Foundation (NBF)

Project Title: *Determine genetic factors that regulate progression to bone marrow failure and myeloid neoplasia in Fanconi anemia.* Role: PI.

07/2020 – 06/2022 -- National Comprehensive Cancer Network (NCCN)

Project Title: *Development of anti-hKIT chimeric antigen receptor T-Cells as a dual hematopoietic stem cell transplantation (HSCT) conditioning and immunotherapeutic agent for cure of pediatric acute myeloid leukemia (AML).* Role: PI.

09/2020 – 08/2023 -- Jasper Therapeutics, Inc.

Project Title: *Treatment of Fanconi Anemia patients in Bone Marrow Failure requiring allogeneic transplant with non-sibling donors at Stanford Lucile Packard Children's Hospital.* Role: PI.

11/2020 – 09/2022 -- Bill and Melinda Gate's Foundation

Project Title: *Exploitation of Hematopoietic Stem Cells Vulnerabilities to Enable in vivo Genome-editing for Correction of Blood and Immune Diseases.* Role: PI.

12/2020 – 12/2022 -- Hyundai Hope on Wheels

Project Title: *Development of anti-KIT antibodies as therapeutics and HSCT conditioning agents for pediatric leukemia.* Role: PI.

09/2021 – 08/2023 -- Department of Defense

Project Title: *Development of Non-Genotoxic Hematopoietic Stem Cell Transplantation Regimens for Fanconi Anemia.* Role: PI.

09/2021 – 08/2022 -- Dunlevie Maternal-Fetal Medicine Center

Project Title: *In-Utero Therapies for Fanconi Anemia.* Role: PI.

B. Prior Funding

2008-2008 HHMI Research Training Fellowship
2008-2010 Paul and Daisy Soros Fellowship
2008-2010 Stanford Medical Scientist Training Program (MSTP)
2015-2017 NIH T32 training grant, Boston Children's Hospital

08/2018 – 12/2021 -- Fanconi Anemia Research Fund, Inc.

Project Title: *Development of a safe, completely non-genotoxic anti-c-Kit (CD117) antibody-based conditioning regimen for hematopoietic stem cell transplantation in Fanconi Anemia.* Role: PI.

10/2018- 09/2020 -- Rocket Pharmaceuticals, Ltd. Sponsored Research Agreement

Project Title: Master Collaboration Agreement for Pre-clinical Studies in Fanconi anemia. Role: PI.

10/2018- 09/2021 -- Stanford Bio-X Seed Grant

Project Title: *Generation of Optimized Adeno-Associated Viruses (AAV) for Hematopoietic Stem Cell Transduction.* Role: PI.

01/2019- 12/2019 -- Pediatric Cancer Research Foundation

Project Title: *Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for Pediatric Acute Myeloid Leukemia (AML).* Role: PI.

05/2019 – 04/2020 -- Baxter Faculty Scholar, Donald E. and Delia B. Baxter Foundation

Project Title: *Combination Lentiviral Gene Therapy and Non-Genotoxic Anti-c-kit (CD117) Antibody Based Conditioning for Curative Treatment of Blood and Immune Diseases.* Role: PI.

01/2020-12/2020 -- Stanford Maternal Child and Health Research Institute

Project Title: *Characterization of Novel Human HSC Cell Surface Receptors*. Role: PI.

01/2020 – 12/2021 -- Andrew McDonough B+ Foundation

Project Title: *Anti-KIT antibodies and immunotoxins as therapies and HSCT conditioning agents for pediatric AML*. Role: PI.

VII. CLINICAL TRIALS

A. Current, On-going Trials with Active Role

- 01/2019 A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A (GENE TRANSFER). Sponsor: Rocket Pharmaceuticals. Role: Prior PI, recently transitioned to Associate Investigator.
- 02/2020 A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A (GENE TRANSFER). Sponsor: Rocket Pharmaceuticals. Role: Prior PI, recently transitioned to Associate Investigator.
- 04/2021 A Phase Ib/IIa Clinical Trial to Evaluate Use of TCR α B $^+$ T-cell/CD19 $^+$ B-cell Depleted Hematopoietic Grafts and a Reduced-Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients with Fanconi Anemia (BMT 373). Sponsor: Matthew Porteus. Role: Prior PI, recently transitioned to Associate Investigator.
- 11/2021 Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102 (GENE TRANSFER). Sponsor: Rocket Pharmaceuticals. Role: Prior PI, recently transitioned to Associate Investigator.

B. Current, On-going Trials with Less Active Role

- 04/2018 An Expanded Access Study Using the CliniMACS System to Offer Therapeutic Manipulated Grafts that are CD34 Cell Enriched and T Cell Depleted for Allogeneic Stem Cell Recipients (BMT 271). Sponsor: Rajni Agarwal. Role: Investigator.
- 12/2019 A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in subjects with Transfusion-Dependent Beta-Thalassemia (GENE TRANSFER). Sponsor: Vertex Pharmaceuticals. Role: Investigator.

C. Current Trials Data Safety Monitoring Board

- 05/2020 In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM). Sponsor: Tippi Mackenzie. Role: Member.

VIII. PATENTS

1. Weissman IL, **Czechowicz A**, Bhattacharya D, Kraft D: "Immunodepletion of Host Bone Marrow for Improved Engraftment in Stem Cell Niche." Provisional Patent Filed 11/3/2006, International Patent Filed 11/2/2007, Patent Granted 9/11/2018.
2. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**: "CRISPR-related Methods and Compositions." US Patent Filed 9/27/2013, International Patent Filed 9/26/2014, Published 8/18/2016.
3. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**, Borisy A: "CRISPR-related Methods and Compositions with Governing gRNAs." US Patent Filed 11/7/2013, International Patent Filed 11/7/2014, Published 8/20/2015, Patent Granted 12/5/2017.
4. Scadden D, Palchaudhuri R, Rossi D, **Czechowicz A**: "Composition and methods for non-myeloablative conditioning." US Patent Filed 4/6/2016, Published 11/29/2018, Patent Granted 2/25/2020.
5. Edge A, Venuti M, **Czechowicz A**. "Expansion and differentiation of inner ear supporting cells and methods of use thereof." US Patent Filed 1/27/2017, Published 01/10/2019.
6. Rossi DJ, **Czechowicz A**, Murphy PM, Li Z. "Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation." US Patent Filed 3/29/2018, Published 6/18/2018.

7. Agarwal R, Long Boyle J, Cowan M, Dvorak C, Kwon H, Le A, Logan A, Pang W, Parkman R, Roncarolo M, Weinberg K, Shizuru J, Prohaska S, **Czechowicz A**. "Hematopoietic Stem Cell Engraftment." US Patent Filed 12/7/2018, Published 12/2/2021.

IX. EDITORIAL SERVICES: Ad Hoc Journal Reviewer

2017-2018	Current Cancer Drug Targets
2018	Blood
2020	Plos ONE
2020	Human Gene Therapy
2020-2021	JCI
2021	Experimental and Molecular Pathology

X. SERVICE AS A GRANT REVIEWER

2017	Reviewer, Stanford SPARK Program
2018	Poster Reviewer, American Society for Gene and Cell Therapy (ASGCT)
2019	Reviewer, NIH Molecular and Cellular Hematology (MCH) Study Section
2019	Reviewer, Fanconi Anemia Research Fund (FARF)
2021	Abstract Reviewer, American Society of Transplantation and Cell Therapy (ASTCT)
2021	Abstract Reviewer, European Society for Blood and Marrow Transplantation (EBMT)

XI. UNIVERSITY ADMINISTRATIVE SERVICES

A. Committee service

2006-2007	Medical School Admissions Student Recruitment Chair, Stanford University
2008-2009	Student Representative, Stanford University Faculty Senate
2010-2011	Student Member, Stanford School of Medicine Faculty Senate
2010-2011	Medical School Representative, Stanford Executive Presidents' Council
2011	Student Member, Committee on Curriculum and Academic Performance (CCAP)
2011	Student Member, MSTP Taskforce
2011	Student Member, Think Tank on Refining Medical Education
2011-2012	Student Representative, Stanford University Board of Trustees
2018-present	Admissions Committee Member, Stanford MSTP, Stanford Biosciences (Immunology and Stem Cell Biology and Regenerative Medicine Graduate Programs)
2021-present	Junior Faculty Committee, Stanford LCME Institution Review

B. Leadership roles

2007-2009	Class President, Stanford Medical Student Association
2007-2008	Co-President, Transplant Interest Group, Stanford School of Medicine
2008-2011	Co-President, Hematology/Oncology Interest Group, Stanford School of Medicine
2009-2010	Student Body President, Stanford Medical Student Association
2010-2011	Student Body Executive President, Stanford Medical Student Association
2019-present	Co-lead, Blood Stem Cell Engineering & Transplantation Platform, Stanford Center for Definitive and Curative Medicine
2020-present	Associate Director of Graduate Studies, Stem Cell Biology and Regenerative Medicine Graduate Student Program

C. Education and Mentorship

2004-2005	BioBridge Counselor, Stanford Biological Sciences Department
2006-2008	BioBridge Graduate Mentor, Stanford Biological Sciences Department
2007	Stanford Medical Youth Science Program Graduate Mentor, Stanford University
2007-2008	Teaching Assistant, Cells to Tissues (INDE 221), Stanford University School of Medicine
2007-2009	Teaching Assistant, Pediatric Chronic Disease (PEDS 281), Stanford University School of Medicine
2008	Group Leader, Stanford Wilderness Experience Activity Trip, Stanford University School of Medicine
2016	Lecturer, Various HMS Courses, Harvard Medical School
2018-present	Lecturer, Various MD and PhD Courses, Stanford University School of Medicine: IMMUNOL 209, PEDS 227, PATH290, RADO204, STEMREM 200, and STEMREM 203

2018-present	Lecturer, Various Residency, Fellowship, Nursing and Administrator seminars, Stanford Children's, Lucile Packard Children's Hospital
2019-present	Mentor, Stanford Women Association of Physician Scientists (SWAPS) Mentorship Program
2020-present	Mentor, Stanford Stem Biology PhD First Year Mentorship Program
2020-present	Committee Member, for Stanford PhD students including chairperson for PhD thesis defense
2020-present	Course Director, IMMUNOL 223: Biology and Disease of Hematopoiesis
2021	Mentor, Stanford MSTP BOOST and Stanford ADVANCE Undergraduate Institute
2021	Group Faculty Mentor, Stanford Pediatrics Fellows Scholarship Academy

XII. SERVICE TO PROFESSIONAL ORGANIZATIONS

A. Membership

2006-present	American Medical Association (AMA)
2008-present	American Society of Hematology (ASH)
2009-present	International Society for Stem Cell Research (ISSCR)
2010-present	American Society of Bone Marrow Transplantation (ASBMT)
2013-present	American Society of Gene and Cell Therapy (ASGCT)
2018-present	American Society for Transplantation and Cellular Therapy (ASTCT)
2019-present	International Society Cell & Gene Therapy (ISCT)
2020-present	International Society for Experimental Hematology (ISEH)

B. Committee Service

2010-2012	International Society for Stem Cell Research (ISSCR): Junior Investigator Committee
2020-present	American Society for Transplantation and Cellular Therapy: Talent Acquisition Task Force
2021-present	Fanconi Anemia Clinical Care: Guidelines Consensus Committee (FACCGCC)

XIII. PRESENTATIONS

A. Invited Speaker / Moderator:

1. Invited Keynote Speaker: "Development of Antibody-based Conditioning Agents for Transplant: Towards More Targeted Therapy?" presented at the 2017 British Society of Bone and Marrow Transplantation, London, England (05/16/2017).
2. Invited Guest Translational Group Speaker: "Discovery of Non-toxic Conditioning Regimens for Stem Cell Therapies" presented at the National Institutes of Health, Washington, DC (4/27/2018).
3. Invited Keynote Speaker Bridges Graduation: "Hematopoietic Stem Cells: A Powerful Platform for The Treatment of Blood and Immune Diseases" presented at San Jose State University, San Jose, CA (5/3/2018).
4. Invited Guest Seminar Speaker: "Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies" presented at the Blood Center of Wisconsin, Waukesha, WI (11/6/2018).
5. Invited Guest Research Seminar Speaker: "Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies" presented at Nationwide Children's Hospital, Columbus, OH (11/9/2018).
6. Invited Symposium Speaker: "Development of Anti-CD117 mAb Conditioning Strategies for Hematopoietic Stem Cell Transplantation" presented at the 2018 Haploidentical Transplantation Symposium (HAPLO2018), San Diego, CA (11/29/2018).
7. Invited Pediatric Grand Rounds, Harvey J. Cohen Endowed Lectureship in Pediatrics Speaker: "Development of Safer Conditioning Strategies for Hematopoietic Stem Cell Transplantation" presented at Lucile Packard Children's Hospital Stanford, Stanford, CA (1/11/2019).
8. Invited Panelist: "Novel Therapeutic Targets" presented at the 2019 In Vivo Gene Therapy & Genome Editing Summit, Miami, FL (3/18/2019).
9. Invited Symposium Speaker: "Updates on the Ongoing Clinical Trials in the US" presented at the 2019 Fanconi Anemia Gene Therapy Symposium, South San Francisco, CA (4/19/2019).
10. Invited Family Camp Speaker: "Update on US Gene Therapy Trial for FA" presented at Camp Sunshine, Casco, ME (6/23/2019).
11. Invited Symposium Speaker: "Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease" at the 2019 Cord Blood Connect International Congress, Orlando, FL (9/13/2019).
12. Invited Conference Speaker: "Future of Blood and Immune Replacement" presented at the Arc Fusion Future of Humans Summit, Boston, MA (12/4/2019).

13. Advisory Board Member Presenter: “Antibody-based Strategies” presented at the CSL Behring Cell Transplant Board Meeting, Miami, FL (1/17/2020).
14. Invited Symposium Speaker: “Updates on the Ongoing Clinical Trials in the US” presented virtually at the 2020 Fanconi Anemia Gene Therapy Symposium, Held online (5/1/2020).
15. Invited Meeting Speaker: “Achieving Selective and Precise In Vivo Targeting and Gene Editing: Key Features of HSCs and Their Environment” presented virtually at the National Institutes of Health -the Bill & Melinda Gates Foundation Expert Scientific Roundtable Webinar Meeting, Held online (5/11/2020).
16. Invited Roundtable Chair: “Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development” at the National Institutes of Health -the Bill & Melinda Gates Foundation Expert Scientific Roundtable Webinar Meeting (5/11/2020)
17. Invited Symposium Speaker: “Improving HSCT Transplantation by Novel Conditioning - How it applies to Allogeneic HSCT” presented virtually at the American Society for Gene and Cell Therapy, Held online (5/12/2020).
18. Invited Seminar Speaker: “Enabling Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the UC Berkeley - Innovative Genomics Institute (IGI) "SIP" Seminar Series (5/19/2020).
19. Invited Speaker: “Stanford Antibody Conditioning Trial” presented virtually at the 2020 Annual Fanconi Anemia Family Meeting/Camp Sunshine, Held online (6/26/2020).
20. Invited Speaker: “Gene Therapy: Stanford Trial & Rocket Pharmaceuticals, Inc.” presented virtually at the 2020 Annual Fanconi Anemia Family Meeting/Camp Sunshine, Held online (6/29/2020).
21. Invited Conference Speaker: “Selective Hematopoietic Stem Cell Ablation using CD117-Antibody-Drug-Conjugates Enables Safe and Effective Transplantation with Immunity Preservation” presented virtually at the 2020 World’s Definitive Antibody-Drug Conjugate Conference, Held online (9/18/2020).
22. Invited Roundtable Chair: “In Utero Gene Therapy Using AAV vectors” at the 2020 International Conference on In Utero Transplantation and Gene Therapy, Held online (10/1/2020).
23. Invited Conference Speaker: “In utero gene Therapy for Fanconi Anemia” presented virtually at the 2020 International Conference on In Utero Transplantation and Gene Therapy, Held online (10/2/2020).
24. Invited Panel Speaker: “Medicine and Healthcare” presented virtually at the Silicon Valley Poland Days, Science and Technology Symposium (10/22/2020).
25. Invited Guest Grand Rounds Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases; Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at City of Hope Grand Rounds, Held online (11/5/2020).
26. Invited Symposium Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the 2020 Sickle Cell Transplant Advocacy and Research Alliance (STAR) Annual Meeting, Held online (11/9/2020).
27. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the 5th Annual Center for Definitive and Curative Medicine (CDCM) Symposium, Held online (2/25/2021).
28. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood & Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the 11th Annual World ADC Europe 2021, Held online (3/10/2021).
29. Invited Speaker: “Antibody-based conditioning in SCID and beyond” presented virtually at the EBMT 2021 Virtual Annual Meeting, Held online (3/16/2021).
30. Invited Faculty Panel: “Showcasing Your Strengths” presented virtually at the Stanford MSTP AUI/BOOST Program, Held online (4/8/2021).
31. Invited Moderator: “Faculty Talks” presented virtually at the 12th Annual Stanford School of Medicine Pediatrics Research Retreat, Held online (4/21/2021).
32. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the Howard Hughes Medical Institute, R3 - Replace, Repair, Regenerate Symposium, Held online (7/21/2021).

33. Invited Speaker: "Gene Therapy for Fanconi Anemia: Interim Results from RP-L102 Global Clinical Trials" presented virtually at the Gene Therapy in Fanconi Anemia: Placing and Replacing FA Genes, Fanconi Anemia Research Foundation Symposium, Held online (7/8/2021).
34. Invited Speaker: "Antibody-conditioning and Fanconi Anemia" presented virtually at the Stanford Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine Division Retreat, Held online (8/12/2021).
35. Invited Speaker: "Stem Cell Transplantation - Where we are now and where we hope to be" presented virtually at the Science Polish Perspectives Meetup USA, Held online (9/17/2021).
36. Invited Speaker: "Regenerative Medicine Session Speaker" presented virtually at the University of California- San Diego, Sanford Stem Cell Symposium, Held online (10/15/2021).
37. Invited Speaker: "Individualized Conditioning Regimens: Antibody Based Conditioning" presented virtually at the Memorial Sloan Kettering Cancer Center, Transplant and Cellular Therapy Options for Non-Malignant Hematologic Disorders Symposium, Held online (10/15/2021).
38. Invited Speaker: "ab T-cell/CD19 B-cell Depleted Haploidentical HSCT Combined with Antibody Conditioning Regimen for Fanconi Anemia" presented virtually at the First International Symposium on $\alpha\beta$ T-cell/CD19 B-cell depleted Haploidentical Stem Cell Transplantation, Held online (10/20/2021).
39. Invited Panel Discussion Moderator: "In Utero Therapies Panel Discussion" presented virtually at the CERSI-FDA Workshop on Prenatal Somatic Cell Gene Therapies, Held online (10/26/2021).
40. Invited Panelist: "Regenerative Medicine and Stem Cell Therapies" presented at the 2021 Convergence Forum, Harwich, MA (10/29/2021).
41. Invited Faculty Speaker: "Compete or perish – HSC dynamics in Fanconi Anemia" presented virtually at the Stanford ReMS Regenerative Medicine Seminar Series, Held online (11/4/2021).
42. Invited Speaker: "Stem Cell and Gene Editing Therapies" presented virtually at the Fetal Therapy: Current Status and Future Directions — Stanford Symposium, Held online (11/9/2021).
43. Invited Speaker: "Breaking biotech's barriers" presented virtually at the 2021 STAT Summit, Held online (11/16/2021).
44. Invited Lecturer: "Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation" presented virtually at the Institute of Transfusion Medicine of Goethe University and German Red Cross Blood Service, Held online (11/17/2021).
45. Invited Speaker: "Fanconi Anemia: From disease biology to current treatments" presented virtually at the Prime Medicine Science Seminar Series, Held online (11/30/2021).
46. Invited Panelist: Poland Days in Silicon Valley 2021 – Post-Pandemic Accelerated Digital World, Held online (12/8/2021)
47. Invited Speaker: "Development of New Treatments for Fanconi Anemia: Gene Therapy and Antibody-Based Stem Cell Transplantation" presented at the National Heart, Lung and Blood Institute's Fellowship Hematology Conference, Held online (1/5/2022).
48. Invited Speaker: "Fanconi Anemia: From disease biology to current treatments" to be presented virtually at the Rome Therapeutics Seminar and Roundtable Discussion, to be held online (3/11/2022).
49. Invited Speaker: "Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation" to be presented virtually at the CSL Research Symposium, to be held online (4/6/2022).
50. Invited Speaker: "Novel Conditioning Methods" to be presented at the 2022 Fanconi Anemia Research Foundation Scientific Symposium, Austin, TX (9/8/2022).

B. Abstracts: Oral Presentations (Last 5 Years; Total of 31):

1. **Czechowicz A**, Palchaudhuri R, Scheck A, Hu Y, Winau F, Hoggatt J, Saez B, Mansour MK, Sykes DB, Scadden D, Rossi D. "Immune Sparing Conditioning for BMT/HSCT Using Anti-Ckit Immunotoxins." Abstract. A Czechowicz presented at the 2018 American Society for Blood and Marrow Transplantation, Salt Lake City, UT (02/23/2018).
2. Gao C, Schroeder A, **Czechowicz A**, Shi Q. " Safe and Effective Platelet-Targeted Gene Therapy of Hemophilia A Enabled Using Non-Genotoxic, Immunotoxin-Based Conditioning." Abstract. Q Shi presented at the 2018 Thrombosis and Hemostasis Societies of North America Meeting, San Diego,

CA (3/10/2018).

3. **Czechowicz A**, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Mansour MK, Sykes DB, Winau F, Scadden D, Rossi D. "Selective HSC Ablation Using Anti-CD117 Antibody-Drug-Conjugate Enables Safe and Effective Murine and Human Hematopoietic Stem Cell Transplantation." Abstract. A Czechowicz presented at the 2018 European Society for Blood and Marrow Transplantation, Lisbon, Portugal (03/19/2018).
4. **Czechowicz A**, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang W, Mansour MK, Tate T, Walck W, Shizuru J, Winau F, Scadden DT, Rossi DJ. " Selective HSC Ablation Using Anti-CD117 Antibody-Drug-Conjugate Enables Safe and Effective Murine and Human Hematopoietic Stem Cell Transplantation." Abstract. A Czechowicz presented at the 2018 American Society of Gene and Cell Therapy, Chicago, IL (5/16/2018).
5. Gao C, Schroeder A, **Czechowicz A**, Shi Q. " Safe and Effective Platelet-Targeted Gene Therapy of Hemophilia A Enabled Using Non-Genotoxic, Antibody-Drug-Conjugate Conditioning." Abstract. Q Shi presented at the 2018 American Society of Gene & Cell Therapy, Chicago, IL (5/16/2018).
6. Li Z, **Czechowicz A**, Scheck A, Rossi D, and Murphy P. "Robust Hematopoietic Mixed Chimerism and Donor-specific Skin Allograft Tolerance after Non-genotoxic anti-CD117 Immunotoxin Conditioning and Donor Bone Marrow Allotransplantation." Abstract. Z Li presented at the 2018 American Transplant Congress, Seattle, WA (6/4/2018).
7. **Czechowicz A**, Palchaudhuri R, Scheck A, Hoggatt J, Saez B, Tate T, Scadden DT, Rossi DJ. "Selective HSC-Ablation Using Anti-CD117 Antibody Drug Conjugate Enables Safe and Effective Hematopoietic Stem Cell Transplantation." Abstract. A Czechowicz presented at the 2018 International Fetal Immunology and Transplantation Society, Stockholm, Sweden (6/12/2018).
8. Chan S, Ko E, Favaro P, Scheck A, **Czechowicz A**. "Development of Safe and Non-Genotoxic anti-c-Kit (CD117) Antibody-based Conditioning Regimens for Hematopoietic Stem Cell Transplantation in Fanconi Anemia." Abstract. A Czechowicz presented at the 2018 Fanconi Anemia Research Foundation Scientific Symposium, Newport Beach, CA (9/29/2018).
9. Gao C, Schroeder JA, Xue F, Jing W, Subramaniam S, Weiler H, **Czechowicz A**, Shi Q. "Using Non-Genotoxic, Antibody-drug-conjugate Conditioning Enables Safe and Effective Platelet-specific FVIII Gene Therapy of Hemophilia A." Q Shi presented at the 2019 American Society of Gene and Cell Therapy, Boston, MA (4/29/2019).
10. **Czechowicz A**, Cory J, Shah D, Roncarolo M. "Non-genotoxic conditioning for hematopoietic cell transplantation in Fanconi Anemia." A Czechowicz presented at the 2019 Fanconi Anemia Research Foundation Symposium, Chicago, IL (9/19/2019).
11. **Czechowicz A**, Roncarolo MG, Beard B, Choi G, Law K, Nicoletti E, Schwartz JD, Soni S. "A Phase I Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Fanconi Anemia, Complementation Group-A: Initial Patient Experience." A Czechowicz presented at the 2019 Fanconi Anemia Research Foundation Scientific Symposium, Chicago, IL (9/21/2019).
12. **Czechowicz A**, Rio P, Bueren J, Beard B, Nicoletti E, Schwartz JD, and Soni S. "Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells." S Soni presented at the 2019 American Society of Transplantation and Cell Therapy, Orlando, FL (2/20/2020).
13. **Czechowicz A**, Agarwal R, Soni S, Beard B, Law K, Nicoletti E, Rio P, Bueren J, Schwartz J, Roncarolo M. "Preliminary Results from a U.S. Phase I Study of Lentiviral Ex-vivo Gene Therapy for Patients with Fanconi Anemia Type A" A Czechowicz presented virtually at the 2020 Fanconi Anemia Scientific Symposium, Held online (9/16/2020).

14. **Czechowicz A**, Pang W, Van Hentenryck M, Thongthip S, Chan S, Walck E, Scheck A, Dejene B, Kwon H, Le A, Dvorak C, Long-Boyle J, Brown J, Logan A, Parkman R, Weissman I, Bertaina A, Weinberg K, Roncarolo M, Shizuru J, Agarwal R. "JSP191 Antibody Conditioning for Hematopoietic Cell Transplantation: Anticipating a New Therapy for Fanconi Anemia" A Czechowicz presented virtually at the 2020 Fanconi Anemia Scientific Symposium, Held online (9/16/2020).
15. MacKenzie T, Frascoi M, Sper R, Lianoglou B, Gonzalez-Velez J, Dvorak C, Kharbanda S, **Czechowicz A**, Vichinsky E. "In utero stem cell transplantation in patients with hemoglobin disorders: anticipating a new therapy for Fanconi Anemia." MacKenzie T presented virtually at the 2020 Fanconi Anemia Scientific Symposium, Held online (9/16/2020).
16. **Czechowicz A**, Agarwal R, Sevilla J, Rio P, Navarro S, Beard B, Law K, Choi G, Zeini M, Nicoletti E, Wagner J, Booth C, Schwartz J, Bueren J, Roncarolo M. "Gene Therapy for Fanconi Anemia, Complementation Group A: Updated Results from Ongoing Global Clinical Studies of RP-L102" A Czechowicz presented virtually at the 2020 American Society of Hematology Meeting, Held online (12/7/2020).
17. **Czechowicz, A**. "Gene Therapy for Fanconi Anemia [Group A]: Interim Results from RP-L102 Global Clinical Trials" A Czechowicz presented virtually at the 2021 Fanconi Anemia Scientific Symposium, Held online (7/8/2021).
18. **Czechowicz A**, Sevilla J, Agarwal R, Booth C, Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M. "Interim Results from Ongoing Global Clinical Trials Evaluating RP-L102 Gene Therapy in Patients with Fanconi Anemia [Group A]." Abstract. A Czechowicz to present at the 2022 American Society of Transplantation and Cell Therapy Meeting, Salt Lake City, UT (4/23/2022).

C. Abstracts: Posters Presentations (Last 5 Years; Total of 23):

1. Pang WW, **Czechowicz A**, Poyser J, Park CY, Weissman IL, Shizuru JA. "Anti-Human CD117 Antibodies Mediate Clearance of Myelodysplastic Syndrome Hematopoietic Stem Cells and Facilitate Establishment of Normal Hematopoiesis in Transplantation." Abstract. WW Pang and A Czechowicz presented at the 2018 American Society for Bone and Marrow Transplantation, Salt Lake City, UT (02/23/2018).
2. **Czechowicz A**, Palchaudhuri R, Li Z, Scheck A, Hu Y, Hoggatt J, Saez B, Pang W, Mansour MK, Tate T, Chan Y, Walck W, Wernig G, Shizuru J, Murphy PM, Winau F, Scadden DT, Rossi DJ. "Selective HSC-Ablation Using Anti-CD117 Antibody Drug Conjugate Enables Safe and Effective Autologous and Allogeneic Hematopoietic Stem Cell Transplantation." Abstract. Featured Poster. A Czechowicz presented at the 2018 International Society of Experimental Hematology, Los Angeles, CA (8/25/2018).
3. Kraft D, Walck E, Carrasco A, Crocker M, Song L, Long M, Najjar S, Nadeem E, Imanbyev G, Mosse M, **Czechowicz A**, McCullough M. "The MarrowMiner: A Novel, Safe, Effective, and Minimally Invasive Device for the Harvest of Bone Marrow Cells." Abstract. Late-Breaking Poster. E Walck and D Kraft presented at the 2019 American Society of Transplantation and Cellular Therapy, Houston, TX (2/23/2019).
4. Gao C, Schroeder JA, Xue F, Jing W, Subramaniam S, Weiler H, **Czechowicz A**, Shi Q. "Using Non-Genotoxic, Antibody-drug-conjugate Conditioning Enables Safe and Effective Platelet-specific FVIII Gene Therapy of Hemophilia A." Abstract. Q Shi presented at the 2019 Congress of International Society on Thrombosis and Haemostasis, Melbourne, Australia (7/7/2019).
5. **Czechowicz A**, Rio P, Bueren J, Beard B, Nicoletti E, Schwartz JD, Soni S. "Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor

- Cells.” Abstract. A Czechowicz presented at the 2019 American Society of Hematology, Orlando, FL (12/8/2019).
6. Bertaina A, Bacchetta R, Lewis D, Grimm P, Shah A, Agarwal R, Conception W, **Czechowicz A**, Bhatia N, Lahiri P, Weinberg K, Parkman R, Porteus M, Roncarolo M. “ $\alpha\beta$ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplantation: A New Platform for Curing Rare and Monogenic Disorders.” Abstract. A Bertaina presented at the 2020 American Society of Transplantation and Cell Therapy, Orlando, FL (2/20/2020).
 7. Van Hentenryck M, Thongthip S, Stone S, Hwang T, Kristovich K, Velez-Bartolomei F, Lee CU, Chu J, Narla A, Sakamoto K, Glader B, Balasa V, Rao L, Agarwal R, Weinberg K, Bertaina A, **Czechowicz A**. “Treatment Resistance in a Fanconi Anemia Mosaic Patient with Myelodysplastic Syndrome.” Abstract. M Van Hentenryck presented virtually at the 2020 Fanconi Anemia Research Fund Scientific Symposium, Held online (9/15/2020).
 8. Agarwal R, Weinberg K, Kwon H, Le A, Long-Boyle J, Kohn D, Bradford K, De Oliveira S, Bertaina A, **Czechowicz A**, Porteus M, Shyr D, Weinacht K, Shah A, Mavers M, Merkel M, Brown J, Dvorak C, Parkman R, Roncarolo M, Shizuru J. “First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency.” Abstract. R Agarwal presented virtually at the 2020 American Society of Hematology Meeting, Held online (12/5/2020).
 9. R Agarwal, CC Dvorak, TB Moore, K Weinberg, HS Kwon, J Long-Boyle, A Le, K Truong, D Kohn, K Bradford, S de Oliveira, A Bertaina, **A Czechowicz**, M Porteus, A Shah, D Shyr, K Weinacht, M Mavers, E Merkel, A Vargas, N Harada, JW Brown, WW Pang, R Parkman, MG Roncarolo, JA Shizuru. “Non-Genotoxic Anti-CD117 Transplant Conditioning in Infants with Newly Diagnosed Severe Combined Immune Deficiency.” Abstract. J Shizuru presented virtually at the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Held online (2/8/2021).
 10. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Rio P, Navarro S, Ancliff P, Beard B, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Rao G, Wagner J, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia [Group A]: Preliminary Results of Ongoing RP-L102 Clinical Trials,” Abstract. A Czechowicz presented virtually at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, Held online (5/11/2021).
 11. Nofal R, Chan Y, Sen S, Hoang H, Thongthip S, **Czechowicz A**. “Development of A Toolbox of Research Studies for Fanconi Anemia.” Abstract. R Nofal presented virtually at the 4th Annual Stanford Maternal and Child Health Research Institute, Held online (10/28/2021).
 12. **Czechowicz A**, Sevilla J, Agarwal R, Booth C, Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2021 American Society of Hematology Meeting, Atlanta, GA (12/13/2021).
 13. Bubb Q, Cheung C, Seir G, Swartzrock L, Richards R, Mackall C, **Czechowicz A**. “Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia.” Abstract. A Czechowicz to present at the 2022 National Comprehensive Cancer Network Annual Conference, Orlando, FL (3/31/2022).
 14. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz to present at the 2022 American Society of Transplantation and Cell Therapy Meeting, Salt Lake City, UT (4/23/2022).

15. **Czechowicz A**, Booth C, Agarwal R, , Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M, Sevilla J. “Ex vivo Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz to present at the 2022 American Society of Gene and Cell Therapy Meeting, Washington, DC (5/16/2022).

XIV. COMMUNITY SERVICE

2005	Roatan Clinical and Public Health Intern, Roatan, Honduras
2011	Little Children of the World Volunteer, Dumaguete City, Philippines
2011	Hematology Visiting Elective Student Volunteer, Christian Medical College, Vellore, India
2014	Stem Cell Transplant Visiting Elective Resident Volunteer, Hôpital Necker Enfants Malades, Paris, France